诺和诺德回应市场份额下滑，中国减重药销售仍在起量

Core Viewpoint - Novo Nordisk's second-quarter performance fell short of market expectations, particularly in the critical U.S. market, where the growth of its GLP-1 drug, semaglutide, has slowed down [1][2] Group 1: Financial Performance - In Q2, Novo Nordisk reported a revenue of 76.86 billion Danish Krone (approximately 11.9 billion USD), marking an 18% increase year-over-year, but below analyst expectations [1] - Semaglutide generated 7.9 billion USD in revenue, accounting for about two-thirds of total revenue, with a year-over-year sales growth of 16% [1] Group 2: Market Challenges - The slowdown in semaglutide sales in the U.S. is attributed to the entry of generic competitors, impacting Novo Nordisk's growth in this key market [2] - In China, semaglutide sales for diabetes have also seen a decline of approximately 11% in the first half of the year [2][3] Group 3: Strategic Responses - Novo Nordisk plans to implement cost-cutting measures, including the termination of eight development projects, to enhance operational efficiency [2] - The company is continuing to invest in future growth, with ongoing late-stage clinical trials for oral semaglutide and a Phase III study for Alzheimer's treatment expected to release data in Q4 [2] Group 4: Market Outlook - Despite the challenges, Novo Nordisk's new weight loss drug sales are gradually increasing, and the company remains optimistic about the Chinese market, which has a significant unmet patient demand [3] - The stock price of Novo Nordisk has dropped over 30% recently, leading to a market capitalization loss of nearly 100 billion USD, prompting analysts to lower target prices and ratings [3]